Skip to main content
CHIMERIC THERAPEUTICS LIMITED logo

CHIMERIC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · CHM ISIN · AU0000121576 ASX Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2024-11-11 Declaration of Voting R…
Country AU Australia
Listing ASX CHM

About CHIMERIC THERAPEUTICS LIMITED

https://www.chimerictherapeutics.com

Chimeric Therapeutics Limited is a clinical-stage cell therapy company focused on the development and commercialization of innovative oncology treatments. The company specializes in chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell therapies designed to target solid tumors and hematologic malignancies. Its lead candidate, CHM 1101 (CLTX CAR T), is a first-in-class therapy utilizing chlorotoxin to target glioblastoma. Additionally, the company is developing CHM 2101, a CDH17-targeted CAR T-cell therapy for gastrointestinal cancers, and the CORE-NK platform, which provides a foundation for off-the-shelf NK cell therapies. By leveraging advanced cellular engineering, Chimeric Therapeutics aims to address significant unmet needs in cancer care through precision medicine and novel therapeutic platforms.

Recent filings

Filing Released Lang Actions
Results of Meeting 2 pages 295.8KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 12 November 2024, titled 'Results of Annual General Meeting'. It provides detailed voting results for resolutions passed at the AGM, including proxy votes and poll outcomes. The content focuses on the official results of shareholder votes at the AGM, referencing ASX Listing Rule 3.13.2 and Corporations Act 2001 Section 251AA, which govern disclosure of voting results. The document does not contain the AGM materials themselves, nor is it a full annual report or financial statement. It is a formal announcement of the voting outcomes from the AGM, fitting the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 3615 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation.
2024-11-11 English
Notice of Extraordinary General Meeting December 2024 21 pages 476.3KB
AGM Information Classification · 95% confidence The document is a Notice of Extraordinary General Meeting (EGM) for Chimeric Therapeutics Limited, detailing the date, time, location, and online access for the meeting. It includes the agenda with resolutions for shareholder approval related to capital raising activities such as the ratification and approval of share placements and issuance of options. The document also contains voting instructions, proxy information, and an explanatory memorandum to assist shareholders in voting decisions. There are no financial statements or detailed financial performance data present, nor is this a transcript or a report of voting results. The content is clearly a meeting notice and related explanatory materials for shareholder decision-making at an EGM. Therefore, the appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during general meetings, including extraordinary ones.
2024-11-04 English
Application for quotation of securities - CHM 6 pages 18.5KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Chimeric Therapeutics Limited regarding the application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references previous announcements (Appendix 3B) related to the securities issuance. The document is an official notice related to the listing or quotation of securities rather than a financial report, earnings release, or management discussion. It is a regulatory announcement about capital market activity, specifically the quotation of securities, which aligns with the category of Share Issue/Capital Change (SHA). The document length is 5527 characters, which is sufficient to contain substantive details about the securities quotation rather than just a brief notice. Therefore, the appropriate classification is SHA.
2024-11-04 English
Notice under section 708A 1 page 219.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement titled 'Notice Under Section 708A(5)(e) of the Corporations Act 2001'. It details the issuance of shares without disclosure under Part 6D.2 of the Corporations Act and confirms compliance with relevant sections of the Corporations Act. The content is a formal regulatory notice about a share issue event, specifically a disclosure notice under the Corporations Act. It is not a full financial report, earnings release, or management discussion. The document length is short (1242 characters), and it is a regulatory announcement about capital raising compliance. This fits the category of Capital/Financing Update (CAP).
2024-11-04 English
Quarterly Activities/Appendix 4C Cash Flow Report 12 pages 995.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report for the Period Ending 30 September 2024' and includes detailed operational updates, clinical trial progress, partnerships, and a financial Appendix 4C cash flow report. The Appendix 4C is a standard quarterly cash flow report required by the ASX Listing Rules, which provides substantive financial data including cash flows from operating, investing, and financing activities for the quarter. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed financial statements and analysis for a quarter strongly indicates this is an Interim / Quarterly Report. The document is not merely an announcement of a report or a certification, nor is it a full annual report or earnings release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2025
2024-10-29 English
Application for quotation of securities - CHM 6 pages 18.3KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and references a previous Appendix 3B announcement regarding a placement. The document is focused on the quotation of securities following a capital raising event. This type of filing is related to capital structure changes and fundraising activities. It is not a full financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is the actual announcement, not just a report publication notice or regulatory filing.
2024-10-23 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.